Pipeline

Conditionally active precision oncology therapeutics

9Bio is committed to advancing highly selective, tumor-targeted therapeutics to broaden the transformative impact of cutting-edge oncology treatments to more patients. Our mission is guided by two key objectives.

First, we leverage our innovative platform to minimize off-tumor target engagement and develop antibody-drug conjugates (ADCs) for tumor antigens previously deemed undruggable due to partial peripheral expression. This approach addresses critical unmet needs in cancer indications where five-year survival rates remain unacceptably low.

Second, by enhancing specificity, we aim to improve the bioavailability and tolerability of our therapeutics, making them more efficacious and accessible to patients who are either contraindicated or often forced to discontinue treatment due to complications arising from comorbidities.

Through these efforts, we strive to advance clinically impactful, broadly applicable, and inclusive therapies — offering renewed hope to cancer patients and their families.

We focus on unlocking the potential of innovative therapeutic modalities, while also leveraging pragmatic value generation of proven targets.

Best-in-class ADC targeting tumor and immune cells

Target indications: Liver and muscle invasive bladder cancers (MIBC)

This program utilizes our tumor-selective technology to engineer a next-generation ADC based on a blockbuster oncology drug nearing patent expiration. With the potential for a rapid return on investment, this ADC introduces novel functionality by killing both tumor and tumor-resident immune cells, while establishing new patent protection and commercial exclusivity.

First-in-class ADC rescuing failed clinical asset

Target indications: Head and neck and metastatic breast cancers

This engineered ADC targets a clinically validated cancer antigen that was abandoned due to on-target, off-tumor toxicity. Designed to eliminate chemotherapy-resistant tumor cells in head and neck and metastatic breast cancers, it overcomes previous safety limitations while preserving promising efficacy observed in three Phase 1 human trials.

The program is being developed in collaboration with the National Research Council Canada (NRC).

First-in-class Cytokine leveraging a novel MoA

Target indications: Stomach and esophageal cancers

This engineered cytokine is designed for cancers refractory to existing therapies via a pioneering mechanism of action (MoA), which has to date remained underexploited due to its toxicity.